Pfizer begins study of oral drug for prevention of COVID-19 By Reuters
(Reuters) -Pfizer Inc said on Monday it has started a mid-to-late-stage study testing its investigational oral antiviral drug for the prevention of COVID-19 infection among those who have been exposed to the virus.
The company and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG (OTC:), have been racing to develop the first antiviral pill for COVID-19.
Pfizer (NYSE:) said it would study the drug, PF-07321332, in up to 2,660 healthy adult participants aged 18 and older who live in the same household as an individual with a confirmed symptomatic COVID-19 infection.
The trial would compare PF-07321332 to a low dose ritonavir. It is an older treatment that’s often used with HIV infections in combination therapies.
Merck and Ridgeback Biotherapeutics announced earlier this month that they have begun to enroll patients in a trial for their experimental drug molnupiravir, which is used to prevent COVID-19.
Pfizer earlier this month also announced that it has begun a middle-to-late stage trial of PF-7321332 in treatment of COVID-19 for adult patients not admitted to a hospital.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.